King Sues Intelliject Over EpiPen Patent Violation

By Martin Bricketto (January 21, 2011, 3:08 PM EST) -- King Pharmaceuticals Inc. and a subsidiary are suing Intelliject Inc. for filing a new drug application that they say breaches a patent covering their EpiPen products for allergic reactions.

In a complaint lodged Wednesday in the U.S. District Court for District of Delaware, King and subsidiary Meridian Medical Technologies Inc. claim the approval of Intelliject's NDA to make and sell an epinephrine auto-injector before the 2025 expiration of the patent would substantially harm the companies.

At issue is U.S. Patent Number 7,794,432 B2, titled "Automatic injector with kickback attenuation" and issued in September 2010.

Columbia, Md.-based Meridian owns that patent and...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!